1. Home
  2. NRDS vs ABUS Comparison

NRDS vs ABUS Comparison

Compare NRDS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NerdWallet Inc.

NRDS

NerdWallet Inc.

HOLD

Current Price

$8.54

Market Cap

720.4M

Sector

Technology

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.28

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRDS
ABUS
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
720.4M
839.5M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
NRDS
ABUS
Price
$8.54
$4.28
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$15.00
$5.00
AVG Volume (30 Days)
956.2K
1.4M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
68.42
55.26
EPS
0.29
0.87
Revenue
$836,600,000.00
$14,083,000.00
Revenue This Year
$10.13
N/A
Revenue Next Year
$7.11
$239.71
P/E Ratio
$28.90
$4.93
Revenue Growth
21.67
128.21
52 Week Low
$7.33
$3.04
52 Week High
$16.24
$5.10

Technical Indicators

Market Signals
Indicator
NRDS
ABUS
Relative Strength Index (RSI) 46.88 47.21
Support Level $7.33 $4.16
Resistance Level $8.81 $4.60
Average True Range (ATR) 0.30 0.18
MACD 0.10 -0.02
Stochastic Oscillator 69.85 30.14

Price Performance

Historical Comparison
NRDS
ABUS

About NRDS NerdWallet Inc.

Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: